by Raynovich Rod | Mar 24, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Macro
Healthcare and Biotech Outperformed the Market During the Recent Sell-off The XLV was up 6.56% in 2025 YTD beating the major stock indices. Two major life sciences funds also outperformed the market: FBIOX and JNGLX. Large caps outperformed small caps among biotechs...
by Raynovich Rod | Mar 17, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 …3/19/25…Another rally day makes 3/4 for SMID caps. ARKG and XBI both up over 1%. 70% of our life science trading stocks are green with nice winners on our focused trades: CRMD,TEM,TWST, PACB, RNA, etc. New buy ADMA at $20 specialty biologics. All...
by Raynovich Rod | Mar 10, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
update-3 3/14—A broad relief rally today after a miserable week took the NAZ up 2.61% and the Russell 2000 up 2.42% and the XBI was flat ending the week at the $87 level. And that was good, Our focus lately has been the SMID cap biotech stocks and they were...
by Raynovich Rod | Mar 3, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2…3/7/25—The market was headed for more losses on Friday during a bad week from tariff chaos when Chairman Powell came on helping calm markets.The healthcare sector continue to avoid tariff issues but we have a few more rounds including...
by Raynovich Rod | Feb 24, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
2/28/25. Upate 2 2/28…Market recovers despite heated Trump/Zelensky exchange. Healthcare still leads the way but importantly buys come into NAZ stocks in last hour up 1.67%. Some nibbles on SMID lifescience stocks with XBI up 1.85% to $88.71: CPRX, CRNX, NVAX,...
by Raynovich Rod | Feb 20, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Large Cap Biopharmaceuticals- Performance Metrics The best performing biopharma stocks YTD were: ABBV up 8.5%, AMGN up 11.8%, AZN up 12%, GILD up 12.7%, LLY up 9.4%, VRTX up 14%. The worst performing biopharmas YTD were: BMY down 4.7%, BIIB, down 10.2%, MRK down...
by Raynovich Rod | Feb 17, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
SMID Biotech Stocks Rallied Nicely the Week of 2/13/25 Selected SMID life science stocks had a good week in a bifurcated market. Large cap biopharmas earnings have been strong and comprise the largest healthcare holdings in our portfolio. Political crosscurrents are a...
by Raynovich Rod | Feb 10, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update-3 ….2/14/25…Happy Valentine’s Day!… RISK ON for MOMENTUM Trades in SMID Life Science List.-Big MOVERS: ABSI, ARKG, BBIO, CRSP, DNLI,,GH, MNMD,PACB, RXRX,TEM, VCYT. We missed TEM up 29% in 5 days. Jumped into REGN too soon down 4.57% In 5...
by Raynovich Rod | Feb 3, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-2 …2/7 1;30 EST Risk off for SMID biotech caps on MACRO news and technicals. XBI down 2%.Renewed tariff threats. BIG tech feeling the heat on CHINA trade war? Consumer sentiment hits 7 month low. Update-1 2/4/25 315p EST…Nice little rally in...
by Raynovich Rod | Jan 27, 2025 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Looks Good for Biotech Stocks-Why we are bullish. Technicals and Relative Strength (RSI) are lined up for bullish trades and good momentum. Biopharmaceuticals offer good value and new themes such as obesity and neuroscience. Innovation and M&A will drive SMID caps...
